Page last updated: 2024-09-05

sorafenib and Carcinoma, Squamous Cell

sorafenib has been researched along with Carcinoma, Squamous Cell in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (17.65)	29.6817
2010's	36 (70.59)	24.3611
2020's	6 (11.76)	2.80

Authors

Authors	Studies
Abbas, MN; Kichenadasse, G; Tan, WS	1
De Rosa, N; Kearney, D; Sidhu, S; Velik, C	1
Feng, YF; Lei, YY; Liu, W; Luo, HH; Yang, HS; Zheng, SY	1
Ghosn, M; Ghosn, S; Halabi-Tawil, M; Kaikati, J; Matar, S	1
Alvarez-Teijeiro, S; Calvo, F; Cutillas, P; Garcia-Pedrero, JM; Hermida-Prado, F; Hijazi, M; Llames, S; Montoro-Jimenez, I; Pevida, M; Prieto-Fernandez, L; Rodrigo, JP; Villaronga, MLA	1
Colmenero, I; Hernández-Martín, Á; Martos-Cabrera, L; Mateos-Mayo, A; Ramírez-Lluch, M; Torrelo, A	1
Beizaei, K; Bußmann, L; Gleißner, L; Hoffer, K; Kriegs, M; Laban, S; Möckelmann, N; Münscher, A; Petersen, C; Rothkamm, K; Steinmeister, L; Vu, AT	1
Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M	1
Banerjee, SK; Hashmi, M; Huang, CH; Leblanc, M; Mehta, S; Moon, J; Rinehart, E; Urba, SG; Williamson, S; Wolf, GT	1
El Tal, AK; Ganger, LK; Mehregan, DA; Remichofsky, CJ	1
Dikomey, E; Gal, A; Gleißner, L; Grénman, R; Grob, TJ; Knecht, R; Kriegs, M; Laban, S; Petersen, C; Steinmeister, L	1
Adelmann, CH; Baccarini, M; Busaidy, NL; Ching, G; Chitsazzadeh, V; Ciurea, AM; Curry, JL; Duvic, M; Dwyer, DW; Ehrenreiter, K; Ma, H; Ojeda, SS; Ruggieri, R; Tannir, NM; Tsai, KY; Vin, H	1
Bhatt, VR; Ganti, AK	1
Holderfield, M; Nagel, TE; Stuart, DD	1
Jiang, L; Liu, H; Liu, X; Shi, G; Wang, X	1
Bernardo, L; Borger, DR; Chen, YB; Durazzo, T; Fathi, AT; Kroshinsky, D; Lin, WM; McAfee, SL; Piris, A; Sadrzadeh, H	1
Aichler, M; Borgmann, DM; Feuchtinger, A; Hauck, SM; Huber, K; Keller, U; Li, Z; Schwaiger, M; Walch, A; Zitzelsberger, H	1
Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M	1
Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL	1
Bedi, A; Bishop, J; Chung, CH; Gilbert, J; Haigentz, M; Leon, ME; Murphy, B; Neil Hayes, D; Nieva, J; Ravi, R; Saba, N; Schell, MJ; Sidransky, D; Tanvetyanon, T; Zhao, X	1
Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C	1
Chang, B; Chen, JC; Chiang, IT; Hsu, FT; Hwang, JJ; Kwang, WK; Liu, YC	1
Chaudary, N; Clarke, B; Fan, S; Fyles, A; Glicksman, R; Haider, M; Hill, RP; Kim, S; MacKay, H; Milosevic, MF; Oza, AM; Pintilie, M; Townsley, CA; Yeung, I	1
Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T	1
Becker, B; Busch, CJ; Dikomey, E; Gleißner, L; Grénman, R; Hoffer, K; Knecht, R; Kriegs, M; Laban, S; Möckelmann, N; Omniczynski, M; Petersen, C; Rieckmann, T; Rothkamm, K; Steinmeister, L	1
Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W	1
Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ	1
Arbiser, JL	1
Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM	1
Aractingi, S; Arnault, JP; Escudier, B; Grange, JD; Malka, D; Mateus, C; Poirier-Colame, V; Robert, C; Sibaud, V; Soria, JC; Spatz, A; Tomasic, G; Wechsler, J	1
Haley, H; Hamza, S; Skelton, HG; Smith, KJ	1
Jaworsky, C; Kish, LS; Kwon, EJ	1
Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J	1
Dingemans, AM; Hochstenbach, MM; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ	1
Guaglianone, PP; Huang, CH; LeBlanc, M; Moon, J; Urba, SG; Williamson, SK; Wolf, GT	1
Li, H; Shi, GH; Wang, CF; Yang, LF; Yang, ZY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y	1
Nelson, KC; Puri, PK; Raymond, AK; Selim, MA; Tyler, DS	1
Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G	1
Donaldson, MR; Smith, JL; Stetson, CL	1
Adnot-Desanlis, L; Bernard, P; Reguiaï, Z	1
Adams, DR; Lynch, MC; Straub, R	1
Dombi, E; Force, J; Giaccone, G; Rajan, A; Steinberg, SM	1
Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A	1
Ardlie, K; Chalk, CJ; Dziunycz, P; Garraway, LA; Hofbauer, GF; Jones, R; Kamsukom, N; Kee, D; MacConaill, LE; McArthur, GA; Oberholzer, PA; Palescandolo, E; Piris, A; Robert, C; Roden, C; Schadendorf, D; Sucker, A	1
André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J	1
Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R	1
Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA	1
Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I	1
Herbst, RS	1
Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A	1
Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E	1

Reviews

5 review(s) available for sorafenib and Carcinoma, Squamous Cell

Article	Year
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2013, Volume: 39, Issue:7 Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib	2013
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. British journal of cancer, 2014, Aug-12, Volume: 111, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Multimerization; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; Vemurafenib	2014
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Critical reviews in oncology/hematology, 2012, Volume: 82, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease Management; Exanthema; Humans; Keratoacanthoma; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Pyridines; Severity of Illness Index; Skin; Sorafenib	2012
Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clinical lung cancer, 2006, Volume: 8 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors	2006
Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbeck's archives of surgery, 2007, Volume: 392, Issue:3 Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib	2007

Trials

10 trial(s) available for sorafenib and Carcinoma, Squamous Cell

Article	Year
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. Head & neck, 2016, Volume: 38, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult	2016
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral oncology, 2015, Volume: 51, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib	2015
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. International journal of radiation oncology, biology, physics, 2016, Jan-01, Volume: 94, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Brachytherapy; Carcinoma, Squamous Cell; Cell Hypoxia; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Time Factors; Tumor Burden; Uterine Cervical Neoplasms	2016
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-10, Volume: 28, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome	2010
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2010
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome	2011
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:7 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Retrospective Studies; Sorafenib; Sulfonamides; Survival Rate; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Young Adult	2011
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Survival Rate	2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes	2012
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Rate	2007

Other Studies

36 other study(ies) available for sorafenib and Carcinoma, Squamous Cell

Article	Year
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. Journal of medical case reports, 2021, Sep-21, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib	2021
Sorafenib-induced eccrine squamous syringometaplasia. The Australasian journal of dermatology, 2022, Volume: 63, Issue:2 Topics: Carcinoma, Squamous Cell; Eccrine Glands; Humans; Metaplasia; Sorafenib	2022
Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration. BMC bioinformatics, 2022, Sep-30, Volume: 23, Issue:1 Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gefitinib; Humans; Oxidative Stress; Prognosis; Sorafenib; Tumor Microenvironment; Tumor Suppressor Protein p53	2022
Disfiguring sorafenib associated eruptive squamous cell carcinomas in a patient with acute myeloid leukemia. Annales de dermatologie et de venereologie, 2023, Volume: 150, Issue:1 Topics: Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Leukemia, Myeloid, Acute; Skin Neoplasms; Sorafenib	2023
Driving role of head and neck cancer cell secretome on the invasion of stromal fibroblasts: Mechanistic insights by phosphoproteomics. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Fibroblasts; Head and Neck Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Secretome; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment	2023
Penile and scrotal infundibular cysts in an adolescent treated with sorafenib. Pediatric dermatology, 2021, Volume: 38, Issue:2 Topics: Adolescent; Carcinoma, Squamous Cell; Humans; Male; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib	2021
Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. Head & neck, 2019, Volume: 41, Issue:1 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crizotinib; ErbB Receptors; Head and Neck Neoplasms; Humans; Indoles; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Sorafenib; Sulfonamides	2019
Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420. Oncology reports, 2013, Volume: 29, Issue:6 Topics: Administration, Oral; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuropilin-1; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Retrospective Studies; Sorafenib	2013
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma. International journal of dermatology, 2013, Volume: 52, Issue:12 Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib	2013
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013, Volume: 109, Issue:2 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Repair; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Radiation-Sensitizing Agents; raf Kinases; Sorafenib; Squamous Cell Carcinoma of Head and Neck	2013
Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Molecular cancer therapeutics, 2014, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinases; raf Kinases; Skin Neoplasms; Sorafenib	2014
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role. Future oncology (London, England), 2014, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Squamous Cell Carcinoma of Head and Neck	2014
Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Guanine Nucleotide Exchange Factors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; T-Lymphoma Invasion and Metastasis-inducing Protein 1; Xenograft Model Antitumor Assays	2014
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-10, Volume: 34, Issue:8 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib	2016
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues. Analytical chemistry, 2014, Nov-04, Volume: 86, Issue:21 Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Immunohistochemistry; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution	2014
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. Molecular medicine reports, 2015, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Hyperplasia; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Burden	2015
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. Anticancer research, 2015, Volume: 35, Issue:4 Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Indoles; Molecular Targeted Therapy; Niacinamide; Papillomaviridae; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib; TOR Serine-Threonine Kinases	2015
Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo. Scientific reports, 2015, Oct-21, Volume: 5 Topics: Animals; Apoptosis; Bone Neoplasms; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Humans; Mice; Mouth Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays	2015
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. BMC cancer, 2016, Jan-19, Volume: 16 Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib; Thyroid Neoplasms	2016
Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. Oncotarget, 2016, Apr-26, Volume: 7, Issue:17 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Proliferation; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib; Tumor Cells, Cultured; X-Rays	2016
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Head & neck, 2017, Volume: 39, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Radiation-Sensitizing Agents; Risk Assessment; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib	2017
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Archives of dermatology, 2008, Volume: 144, Issue:6 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib	2008
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma. The Journal of investigative dermatology, 2009, Volume: 129, Issue:3 Topics: Aneuploidy; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Squamous Cell; Gene Expression Regulation, Neoplastic; Mice; Mice, Transgenic; Models, Biological; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A	2009
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clinical genitourinary cancer, 2009, Volume: 7, Issue:1 Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Inflammation; Keratoacanthoma; Keratosis, Actinic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2009
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Follow-Up Studies; Humans; Keratinocytes; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Time Factors	2009
Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2009, Volume: 35, Issue:11 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Humans; Keratoacanthoma; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2009
The histologic spectrum of epithelial neoplasms induced by sorafenib. Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Epithelium; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2009
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib; Survival Rate; Treatment Outcome	2010
Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urologia internationalis, 2010, Volume: 85, Issue:3 Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Penile Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2010
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Archives of dermatology, 2010, Volume: 146, Issue:12 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes; Follow-Up Studies; Humans; Leg; Male; Melanoma; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib	2010
Invasive squamous cell carcinoma and sorafenib in a black patient. Archives of dermatology, 2011, Volume: 147, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2011
[Squamous cell carcinoma in a patient receiving sorafenib]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cooperative Behavior; Follow-Up Studies; Humans; Interdisciplinary Communication; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A	2011
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Humans; Keratoacanthoma; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Mass Spectrometry; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2012
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-01, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cells, Cultured; Female; Humans; Keratinocytes; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyridines; raf Kinases; ras Proteins; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Skin; Skin Neoplasms; Sorafenib; Tumor Suppressor Protein p53; Ultraviolet Rays	2012
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins	2012